Royalty Pharma plc (RPRX) · INSIDERData sourcesSEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago
Public companyRoyalty Pharma plc
RPRXCIK 0001802768
Price$68.83
1 year+68.8%
Disclosed transactions60
Buys / sells0 / 39
Max Insider Score33
Connections with evidence8
RPRX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 6 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Derivative conversion | C | — 15.0K sh | Nov 6, 2026 | Nov 6, 2026 |
| 2 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Derivative conversion | C | — 150.0K sh | Nov 6, 2026 | Nov 6, 2026 traded Nov 6, 2026 | +0d | SEC Form 4 | |
| 2 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Grant or award | A | — 5,341 sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 2 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Grant or award | A | — 7,122 sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 5 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Grant or award | A | — 7,122 sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 2 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 100.0K sh | Nov 6, 2026 | Nov 6, 2026 traded Nov 6, 2026 | +0d | SEC Form 4 | |
| 9 | LGLegorreta Pablo G.Director, CEO, Chairman of the Board | RPRXRoyalty Pharma plc Grant or award | A | — 42.2K sh | Nov 4, 2026 | Nov 6, 2026 traded Nov 4, 2026 | +2d | SEC Form 4 | |
| 2 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 10.0K sh | Nov 6, 2026 | Nov 6, 2026 traded Nov 6, 2026 | +0d | SEC Form 4 | |
| 6 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 15.0K sh | Nov 6, 2026 | Nov 6, 2026 traded Nov 6, 2026 | +0d | SEC Form 4 | |
| 2 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Derivative conversion | C | — 150.0K sh | Nov 6, 2026 | Nov 6, 2026 traded Nov 6, 2026 | +0d | SEC Form 4 | |
| 18 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $239K 4,126 sh | Sep 28, 2026 | Sep 30, 2026 traded Sep 28, 2026 | +2d | SEC Form 4 | |
| 9 | BLBassler Bonnie LDirector | RPRXRoyalty Pharma plc Grant or award | A | $37K 642 sh | Sep 30, 2026 | Sep 30, 2026 traded Sep 30, 2026 | +0d | SEC Form 4 | |
| 9 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $231K 3,927 sh | Sep 22, 2026 | Sep 24, 2026 traded Sep 22, 2026 | +2d | SEC Form 4 | |
| 23 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $5.62M 96.1K sh | Sep 22, 2026 | Sep 24, 2026 traded Sep 22, 2026 | +2d | SEC Form 4 | |
| 10 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Gift · 10b5-1 plan | G | — 16.8K sh | Aug 19, 2026 | Aug 19, 2026 traded Aug 19, 2026 | +0d | SEC Form 4 | |
| 23 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $6.00M 100.0K sh | Aug 18, 2026 | Aug 19, 2026 traded Aug 18, 2026 | +1d | SEC Form 4 | |
| 18 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $105K 1,772 sh | Aug 13, 2026 | Aug 17, 2026 traded Aug 13, 2026 | +4d | SEC Form 4 | |
| 21 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $541K 9,230 sh | Aug 13, 2026 | Aug 17, 2026 traded Aug 13, 2026 | +4d | SEC Form 4 | |
| 2 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Grant or award | A | — 11.0K sh | Aug 5, 2026 | Aug 7, 2026 traded Aug 5, 2026 | +2d | SEC Form 4 | |
| 5 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Gift | G | — 18.5K sh | Aug 7, 2026 | Aug 7, 2026 traded Aug 7, 2026 | +0d | SEC Form 4 | |
| 5 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Grant or award | A | — 11.0K sh | Aug 5, 2026 | Aug 7, 2026 traded Aug 5, 2026 | +2d | SEC Form 4 | |
| 2 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Grant or award | A | — 8,252 sh | Aug 5, 2026 | Aug 7, 2026 traded Aug 5, 2026 | +2d | SEC Form 4 | |
| 5 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Gift | G | — 3,000 sh | Aug 7, 2026 | Aug 7, 2026 traded Aug 7, 2026 | +0d | SEC Form 4 | |
| 9 | BLBassler Bonnie LDirector | RPRXRoyalty Pharma plc Grant or award | A | $37K 689 sh | Jun 30, 2026 | Jun 30, 2026 traded Jun 30, 2026 | +0d | SEC Form 4 | |
| 19 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.75M 32.4K sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC Form 4 | |
| 17 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $502K 9,098 sh | Jun 24, 2026 | Jun 25, 2026 traded Jun 24, 2026 | +1d | SEC Form 4 | |
| 23 | HCHite ChristopherEVP & Chairman, Partnering | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $6.41M 117.6K sh | Jun 23, 2026 | Jun 25, 2026 traded Jun 23, 2026 | +2d | SEC Form 4 | |
| 19 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.64M 32.9K sh | Apr 28, 2026 | Apr 30, 2026 traded Apr 28, 2026 | +2d | SEC Form 4 | |
| 1 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $93K 1,875 sh | Apr 28, 2026 | Apr 30, 2026 traded Apr 28, 2026 | +2d | SEC Form 4 | |
| 1 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $85K 1,875 sh | Mar 23, 2026 | Mar 25, 2026 traded Mar 23, 2026 | +2d | SEC Form 4 | |
| 15 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.50M 32.9K sh | Mar 23, 2026 | Mar 25, 2026 traded Mar 23, 2026 | +2d | SEC Form 4 | |
| 14 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Grant or award | A | — 20.0K sh | Feb 11, 2026 | Feb 13, 2026 traded Feb 11, 2026 | +2d | SEC Form 4 | |
| 14 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Grant or award | A | — 26.6K sh | Feb 11, 2026 | Feb 13, 2026 traded Feb 11, 2026 | +2d | SEC Form 4 | |
| 9 | HCHite ChristopherEVP & Vice Chairman | RPRXRoyalty Pharma plc Grant or award | A | — 26.6K sh | Feb 11, 2026 | Feb 13, 2026 traded Feb 11, 2026 | +2d | SEC Form 4 | |
| 21 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $805K 20.0K sh | Jan 23, 2026 | Jan 26, 2026 traded Jan 23, 2026 | +3d | SEC Form 4 | |
| 22 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $2.59M 65.8K sh | Jan 20, 2026 | Jan 23, 2026 traded Jan 20, 2026 | +3d | SEC Form 4 | |
| 16 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $148K 3,750 sh | Jan 20, 2026 | Jan 23, 2026 traded Jan 20, 2026 | +3d | SEC Form 4 | |
| 20 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $790K 20.0K sh | Jan 16, 2026 | Jan 20, 2026 traded Jan 16, 2026 | +4d | SEC Form 4 | |
| 20 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $816K 20.0K sh | Jan 9, 2026 | Jan 13, 2026 traded Jan 9, 2026 | +4d | SEC Form 4 | |
| 16 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $786K 20.0K sh | Dec 26, 2025 | Dec 29, 2025 traded Dec 26, 2025 | +3d | SEC Form 4 | |
| 16 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $768K 20.0K sh | Dec 19, 2025 | Dec 22, 2025 traded Dec 19, 2025 | +3d | SEC Form 4 | |
| 24 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.18M 30.7K sh | Dec 18, 2025 | Dec 19, 2025 traded Dec 18, 2025 | +1d | SEC Form 4 | |
| 24 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $3.06M 79.3K sh | Dec 17, 2025 | Dec 19, 2025 traded Dec 17, 2025 | +2d | SEC Form 4 | |
| 33 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $714K 18.2K sh | Dec 5, 2025 | Dec 9, 2025 traded Dec 5, 2025 | +4d | SEC Form 4 | |
| 25 | UMUrist MarshallEVP, Research & Investments | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $914K 23.3K sh | Dec 5, 2025 | Dec 9, 2025 traded Dec 5, 2025 | +4d | SEC Form 4 | |
| 29 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $4.38M 110.0K sh | Dec 3, 2025 | Dec 5, 2025 traded Dec 3, 2025 | +2d | SEC Form 4 | |
| 18 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $121K 3,126 sh | Nov 24, 2025 | Nov 26, 2025 traded Nov 24, 2025 | +2d | SEC Form 4 | |
| 11 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $24K 624 sh | Nov 24, 2025 | Nov 26, 2025 traded Nov 24, 2025 | +2d | SEC Form 4 | |
| 24 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $2.13M 55.1K sh | Nov 24, 2025 | Nov 26, 2025 traded Nov 24, 2025 | +2d | SEC Form 4 | |
| 17 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $406K 10.7K sh | Nov 24, 2025 | Nov 26, 2025 traded Nov 24, 2025 | +2d | SEC Form 4 | |
| 31 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.81M 47.4K sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 31 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $1.83M 47.8K sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 21 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $181K 4,628 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 25 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $179K 4,599 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 28 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $977K 25.5K sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 25 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $96K 2,470 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 25 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $106K 2,770 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 22 | LWLloyd George W.EVP, Investments & CLO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $8,978 230 sh | Nov 19, 2025 | Nov 21, 2025 traded Nov 19, 2025 | +2d | SEC Form 4 | |
| 17 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $147K 3,750 sh | Nov 17, 2025 | Nov 19, 2025 traded Nov 17, 2025 | +2d | SEC Form 4 | |
| 23 | CPCoyne Terrance P.EVP & CFO | RPRXRoyalty Pharma plc Open-market sale · 10b5-1 plan | SELL | $2.59M 65.8K sh | Nov 17, 2025 | Nov 19, 2025 traded Nov 17, 2025 | +2d | SEC Form 4 | |
EVP, Investments & CLO · Nov 7, 2025
Planned sales and 5% stakes
Form 144, 13D and 13G